

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT STRATEGIC COLLABORATION AGREEMENT WITH QUANTOBIO

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company entered into a strategic collaboration framework agreement (the “**Strategic Collaboration Agreement**”) with Beijing QuantoBio Biotechnology Co., Ltd. (北京曠博生物技術股份有限公司) (“**QuantoBio**”) on August 4, 2021, pursuant to which, both parties agreed to carry out strategic cooperation on the development, registration, manufacturing and sales of flow cytometry and accessory products in the field of, among others, mirror detection, multi-factor detection and infectious substance detection.

QuantoBio is a company established in the PRC and listed on the National Equities Exchange and Quotations (stock code: 835093) focusing on developing and producing biological reagent products for scientific research and clinical diagnosis. To the best knowledge of the Directors, QuantoBio is an independent third party to our Company.

By Order of the Board

Suzhou Basecare Medical Corporation Limited

Dr. Liang Bo

Chairman and General Manager

Suzhou, PRC, August 4, 2021

As of the date of this announcement, the Board comprises Mr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Mr. KANG Xixiong, Mr. HUANG Taosheng and Mr. YU Kwok Kuen Harry as independent non-executive Directors.